I'm looking
for help...
Aidpage is free!
   

Free downloads: GrantGate®  Federal Money Retriever®

NCI COMPETING CONTINUATION SBIR/STTR PHASE II GRANTS FOR CANCER DIAGNOSIS, PREVENTION AND TREATMENT

Published on AidPage by IDILOGIC on Jun 24, 2005
Administered by:

Department of Health and Human Services, National Institutes of Health, National Institutes of Health
(see all US Federal Agencies)

Explore all postings for this grant program:
Applications Due:


Multiple Receipt Dates - See Link to Full Announcement for details.

total funding: Not Available
max award: $750,000
min award: none
cost sharing, matching: No
number of awards: Not Available
type of funding: Grant
Description:

The Small Business Innovation Research (SBIR) and Small Business Technology
Transfer (STTR) programs were initiated as a means for government agencies to use
small businesses to stimulate technological innovation and to help agencies meet
their research and development (R AND D) needs. An additional provision of these
programs is the expected commercialization of the research. Certain types of
research require clinical evaluation and Federal regulatory approvals before the
Phase III part of the small business research pathway can ever be realized. A
recipient of a NIH SBIR/STTR Phase I and Phase II award normally receives no more
than $1 million. If the intended commercialized product is a medical device, drug,
biologic or diagnostic assay, the $1 million often represents a small fraction of
the funds necessary to complete the studies required for approval and licensing by
the Food and Drug Administration (FDA) or other Federal agencies and for clinical
evaluation.
While a recipient of an NIH SBIR/STTR Phase I and Phase II award normally receives
less than three years of support, the process of moving promising new products
from bench to bedside typically may take more than a decade. The drug discovery
timeline, for example, starts with identification of an agent or class of agents
with particular activities; identification and optimization of lead compounds; and
subsequent pre-clinical testing of these compounds for safety and toxicity. Those
agents still considered viable after such rigorous scrutiny are then brought to
human subjects for clinical evaluation of various aspects of the agent, including
safety, toxicity, effectiveness, and dosage determination. Similarly, long
timelines are required for other products intended to understand, diagnose,
prevent, or treat human health disorders (e.g., medical devices, vaccines).
Despite the cost and the length of time required to move such products from the
laboratory to the patient, these are products with potential to contribute
significantly to the economy of the nation and to the health of her people. The
intent of the competing continuation SBIR/STTR Phase II grants is to support such
research and development and its translation into the clinic.
The purpose of this Program Announcement (PA) is to solicit grant applications for
the competing continuation of previously funded Phase II SBIR/STTR grants that
propose to continue the process of developing products for commercialization that
ultimately require: 1) approval of a Federal regulatory agency and 2) clinical
evaluation up to "proof of principle" demonstration, generally only through a
Phase II clinical trial. Such products include, but are not limited to: drugs,
vaccines, radioligands, biomarkers, medical implants or devices, imaging protocols
proposed for clinical use, new software for instrument performance, and diagnostic
or predictive assays applicable for cancer diagnosis, prevention, and treatment.

Who can apply:

Anyone/General Public
City Or Township Governments
County Governments
Federally Recognized Indian Tribal Governments
Independent School Districts
Individual/Family
Minority Group
Native American Organization
Non-Government - General
Nonprofits Having A 501(C)(3) Status With The IRS, Other Than Institutions Of Higher Education
Nonprofits That Do Not Have A 501(C)(3) Status With The IRS, Other Than Institutions Of Higher Education
Other Private Institution/Organization
Private Institutions Of Higher Education
Private Nonprofit Institution/Organization (Includes Institutions Of Higher Education, Hospitals)
Profit Organization
Public And State Controlled Institutions Of Higher Education
Public Housing Authorities/Indian Housing Authorities
Small Business (Less Than 500 Employees
Special District Governments
State (Includes District Of Columbia; Includes Institutions Of Higher Education And Hospitals)
U.S. Territories And Possessions (Includes Institutions Of Higher Education, Hospitals)

Eligible functional categories:
Funding Sources:

Cancer Biology Research
Cancer Cause and Prevention Research
Cancer Control
Cancer Detection and Diagnosis Research
Cancer Treatment Research

More Information:

http://grants.nih.gov/grants/guide/pa-files/PA-04-047.html

If you have problems accessing the full announcement, please contact: Webmaster, NIH

Address Info:

Office of Extramural Programs 6705 Rockledge Drive Bethesda, MD 20892-7963

SPONSORED LINKS
Free downloads: GrantGate®  Federal Money Retriever®
Apply for grants and loans! Click here to start